Cresco Labs (CRLBF) Notes Payables (2019 - 2025)

Cresco Labs' (CRLBF) quarterly Notes Payables came in at $10.8 million in Q4 2025, down 51.54% on a QoQ basis from $22.3 million in Q3 2024.

Cresco Labs (CRLBF) Notes Payables (2019 - 2025) Analysis & Trends

Cresco Labs (CRLBF) has 7 years of Notes Payables data on file, last reported at $10.8 million in Q4 2025.

Quarterly Notes Payables changed N/A year-over-year to $10.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10.8 million (changed N/A YoY) and the FY2025 annual result came in at $10.8 million, changed N/A from the prior year.
Notes Payables slipped to $10.8 million in Q4 2025, from $22.3 million in the prior quarter.
In the past five years, Notes Payables ranged from a high of $29.2 million in Q1 2022 to a low of $10.8 million in Q4 2025.
A 5-year average of $19.0 million and a median of $19.9 million in 2021 frame the typical range for Notes Payables.
Annual changes were most pronounced in 2021 — Notes Payables surged 217.85% — and 2022, when it rose 4.24%.
Tracing CRLBF's Notes Payables over 5 years: stood at $19.9 million in 2021, then surged by 46.54% to $29.2 million in 2022, then tumbled by 59.53% to $11.8 million in 2023, then soared by 88.33% to $22.3 million in 2024, then tumbled by 51.54% to $10.8 million in 2025.
The last three Notes Payables figures came in at $10.8 million (Q4 2025), $22.3 million (Q3 2024), and $12.3 million (Q2 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-
10	Cresco Labs	290.46 Mn	226.34 Mn	86.95 Mn

Download Data